However, the GVAX + αPD-1 and CCR2/5i + αPD-1 treatment groups significantly enhanced IFN-γ production from CD8+ T cells isolated from the tumor and spleen compared with CCR2/5i alone. This evidence concerns the gene CD8A and neoplasm.